PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross Blue Shield of MassachusettsCommercial · Coverage · Medical Policy · MA · Cardiology, Urology, Genetics +3 moreMedium impact

Medical Policy Updates for December 2026

Act
by Sep 1, 2026
Effective date
Sep 1, 2026
Identified
Sep 2, 2026

Summary

This policy update affects five specialties with changes effective September 1, 2026 through December 1, 2026. Key changes include: (1) CPT codes 0338T and 0339T added to Renal Denervation policy with no prior auth required; (2) Genetic testing codes 81265 and 81266 no longer require prior authorization (effective September 19, 2026); (3) CA 125 test now covers BRCA1, BRCA2, and Lynch Syndrome indications; (4) Serum Tumor Markers policy expanded to include medullary thyroid cancer; (5) Ferric Carboxymaltose replaces Injectafer in Medicare Advantage Step Therapy. All changes require no provider action and prior authorization is not required for affected services.

Get alerts when payers change rules like this one

We check Blue Cross Blue Shield of Massachusetts and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross Blue Shield of Massachusetts alertsPolicy Monitoring is free. No card required.

What to do

by Sep 1, 2026 · 5 steps
01Billing team must update systems to remove prior authorization requirement for Ferric Carboxymaltose (Medicare Advantage Part B Step Therapy policy 020) and remove Injectafer from coverage.
02By September 19, 2026: Update billing system to reflect that CPT codes 81265 and 81266 no longer require prior authorization for all products.
03By December 1, 2026: Update system edits and claim processing for CPT codes 0338T and 0339T (Renal Denervation) to reflect no prior authorization required; ensure CA 125 test (Policy 503) processes without prior auth for new indications (BRCA1, BRCA2, Lynch Syndrome); update Serum Tumor Markers policy (Policy 538) to process claims for medullary thyroid cancer indication without prior auth.
04Notify billing and clinical staff that these policy changes require no proactive provider actions.
05Update internal policy reference documentation to reflect new covered indications and code additions.

Codes mentioned

8126581266

Original notice

Medical Policy Updates for December 2026
bluecrossma.org · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account